ABSTRACT

The invention provides 5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one compounds that are selective inhibitors of KDR and FGFR kinases, and are useful in the treatment of cancers. The compounds have the generic structure I



I

where Ar, Ar', and R^1 are as set forth in the present specification. The invention also provides pharmaceutical compositions containing these compounds and methods for their use.